PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustion
Authors:
- Teresa DinterTDTeresa Dinter
- Sebastian MackowiakSMSebastian Mackowiak
- Zachary J. RogersZRZachary J. Rogers
- Vidit BhandarkarVBVidit Bhandarkar
- Molly Y. CarneyMCMolly Y. Carney
- Yiming J. ZhangYZYiming J. Zhang
- Duncan MorganDMDuncan Morgan
- Lorelai PopLPLorelai Pop
- Fiona ChatterjeeFCFiona Chatterjee
- Emi LutzELEmi Lutz
- Yajit JainYJYajit Jain
- Adityanarayanan RadhakrishnanARAdityanarayanan Radhakrishnan
Preprint
Abstract
In cancer, CD8 + T cell responses are dominated by exhausted T cells, which can be reinvigorated using immune checkpoint blockade therapy and can control large tumors. However, it remains unclear which T cell fate best supports long-term immunity following tumor regression or clearance and a period of minimal antigen load. This question is particularly relevant following surgical tumor resection, when tuning the immune system could prevent recurrence. To determine which T cell fate provides durable protection following surgery and metastatic rechallenge, we modulated T cell priming using anti-PD-1, IFN-β or agonistic anti-CD40 and assessed effects on CD8 + T cell differentiation and overall survival. IFN-β and anti-CD40 promoted effector and memory-like T cell states, respectively, whereas anti-PD-1 did not markedly alter T cell differentiation, yet conferred the greatest survival benefit against metastatic tumors. Notably, anti-PD-1 induced epigenetic remodeling, which was detectable upon metastatic recall, consistent with the maintenance of a circulatory intermediate-exhausted T cell state. Thus, while effector and memory precursor-like T cells could be generated with IFN-β and agonistic anti-CD40, only the intermediate-exhausted T cell state driven by anti-PD-1 supported durable anti-tumor immunity. Summary: This study shows that PD-1 blockade during T cell priming promotes a circulatory intermediate-exhausted CD8⁺ T cell state that uniquely supports durable anti-tumor immunity after surgical resection and metastatic challenge, outperforming effector or memory-like T cell responses generated by IFN-β or CD40 agonist treatment, respectively.Keywords
Funding Information
- National Cancer Institute (P30-CA14051)
- Ludwig Center MIT (n/a)
This publication has 65 references indexed in Scilit:
- Id2 levels determine the development of effector vs. exhausted tissue-resident memory CD8+ T cells during CNS chronic infectionCell Reports, 2025
- The transcription regulator ID3 maintains tumor-specific memory CD8+ T cells in draining lymph nodes during tumorigenesisCell Reports, 2024
- Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cellsCell Reports, 2021
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade ImmunotherapyImmunity, 2019
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaCell, 2018
- The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and HomeostasisImmunity, 2016
- T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune Response to Chronic Viral InfectionsImmunity, 2016
- Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter DropletsCell, 2015
- Determination and Inference of Eukaryotic Transcription Factor Sequence SpecificityCell, 2014
- Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysisEuropean Journal of Immunology, 2003